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Abstract
Background: Multiple sclerosis is a chronic disease of uncertain aetiology. Variations in its disease
course make it difficult to impossible to accurately determine the prognosis of individual patients.
The Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR) developed an "online analytical
processing (OLAP)" tool that takes advantage of extant clinical trials data and allows one to model
the near term future course of this chronic disease for an individual patient.
Results: For a given patient the most similar patients of the SLCMSR database are intelligently
selected by a model-based matching algorithm integrated into an OLAP-tool to enable real time,
web-based statistical analyses. The underlying database (last update April 2005) contains 1,059
patients derived from 30 placebo arms of controlled clinical trials. Demographic information on the
entire database and the portion selected for comparison are displayed. The result of the statistical
comparison is provided as a display of the course of Expanded Disability Status Scale (EDSS) for
individuals in the database with regions of probable progression over time, along with their mean
relapse rate. Kaplan-Meier curves for time to sustained progression in the EDSS and time to
requirement of constant assistance to walk (EDSS 6) are also displayed. The software-application
OLAP anticipates the input MS patient's course on the basis of baseline values and the known
course of disease for similar patients who have been followed in clinical trials.
Conclusion: This simulation could be useful for physicians, researchers and other professionals
who counsel patients on therapeutic options. The application can be modified for studying the
natural history of other chronic diseases, if and when similar datasets on which the OLAP operates
exist.
Background
Multiple sclerosis (MS) is an inflammatory disease of the
central nervous system. Currently there is no cure for MS,
but there are treatments for its relapsing forms that reduce
the short and mid-range impact of the disease. It remains
impossible to accurately predict the prognosis of individ-
ual patients, which could be important for patient coun-
selling and in weighing therapeutic options. The Sylvia
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data from clinical trials and natural history studies to
develop mathematical models for the course of the dis-
ease which might assist in the efforts to accurately deter-
mine short, mid and long-range prognosis. The
"individual risk profile" project makes the Centre's large
database available to health care professionals via access
to a representative part of the database.
Implementation
The SLCMSR database consist of data from most natural
history studies and the placebo arms of nearly all ran-
domised controlled clinical trials in MS patients from the
last decade. The data are anonymised, homogenized and
pooled from the academic and corporate sources. As of
April 2005, 45 separate data sets and 81,000 patient-years
of data from 20,000 patients were included. The database
is divided into so-called "open" and "closed" parts. The
"open" database is accessible by researchers (and in the
future possibly other professionals) at their discretion.
The "closed" database is accessible only to authorized staff
on behalf of the Validation Committee of the Centre as
part of the validation policy of the SLCMSR [1].
An interdisciplinary team of neurologists, information
technology specialists, and biostatisticians developed a
Java-based OLAP tool using the statistical software pack-
age R 2.0.1 [2,3]. The source code is available in Addi-
tional file 1. For validation purposes essential parts were
independently re-programmed using SAS/INTRNET [4].
Remote users are able to trigger powerful statistical soft-
ware programs running on the host computer using a sim-
ple graphical interface displayed in a standard browser.
The results of the analysis are displayed in real time.
Registered OLAP users access the database via their inter-
net browser, select values for patient characteristics of
their interest and get displays of the observed disease
course for placebo patients from the database with match-
ing characteristics.
Results
The essential component of the OLAP is a matching algo-
rithm. A given patient of interest is "identified" by a set of
covariates which are widely accepted to be potential prog-
nostic factors [5-7]: the number of relapses in the last 12
months, disease duration from diagnosis, age at disease
onset, disability level as measured by the Expanded Disa-
bility Status Scale (EDSS) [8], and disease course [9] –
either relapsing remitting, secondary progressive, primary
progressive or clinically isolated syndrome [10,11]. The
matching algorithm then automatically selects the most
similar subgroup of patients that are included in the
banked database, with similarity defined by the covariates
on a disease course specific outcome. The resulting display
shows the disease course of all patients in the database
that are similar to the patient of interest, and this informa-
tion can be used to project a hypothesized outcome for
the patient of interest, based on the behaviour of similar
patients in the database.
This descriptive report is based on 1,059 patients from
placebo arms of controlled clinical trials available from
release 1.0 of the SLCMSR database (April 2005).
The patient baseline characteristics of the database are
summarized in table 1. The data from patients in the data-
set agree well with the literature reports concerning sex
ratio, age at disease onset, duration of disease and relapse
Table 1: Descriptive statistics of clinical trial, placebo arm MS patients derived from the open data set of the SLCMSR and included in 
"Individual Risk Profile" OLAP-tool, version 2.0.0, divided by the four different courses CIS clinically isolated syndrome, RR relapsing 
remitting, SP secondary progressive and PP primary progressive. 
Disease subtype
Database patient characteristics CIS RR SP PP
No. of patients 124 460 455 20
Sex ratio (m/f) 0.38 0.41 0.69 0.82
Age at onset (Median and 5%- and 95%- percentile) 30 [19;40] 29 [17;41] 29 [18;45] 37 [19;57]
Baseline EDSS (Median and 5%- and 95%- percentile) 1.5 [0.0;5.0] 2.5 [1.0;5.5] 5.5 [3.0;6.5] 3.5 [1.5;6.0]
Duration (months) (Median and 5%- and 95%- percentile) 2 [0;104] 66 [7;225] 148 [40;341] 50 [11;190]
Relapses last 12 months:
no relapse
5 47 256 6
Relapses last 12 months:
1 relapse
115 131 97 4
Relapses last 12 months:
2 or more relapses
0 132 36 1
Relapses last 12 months:
unknown
4 150 66 9
The values in brackets are the 5%- and 95%- percentile.Page 2 of 6
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[6,7]. Demographic information of the selected subgroup
is displayed in comparison to the requested characteristics
and to demographics of all patients available with the
same disease course (see figure 1). Output is provided
either as a display of the change of EDSS for individuals in
the database over time, regions of progression over time
along with the mean relapse rate, or the Kaplan-Meier
curve of time to sustained progression in EDSS and time
to progression to EDSS 6 (the time of constant assistance
to walk) (see figures 2 and 3).
Discussion
The advantages of OLAP-tools based on a unified data-
base ("data warehousing") are widely applied in business
and increasingly used in medical research and medical
decision-making. In this report we describe a tool for
investigating the course of MS based on specific clinical
data and using that information to project disease course
in patients of interest.
The predictive power of this tool is limited by restrictions
of the composition of patients and duration of observa-
tions in the current release of the database. The clinical
data are restricted to data from the placebo groups of ran-
domized clinical trials, which may not reflect disease out-
comes in patients not involved in clinical trials and
certainly do not reflect the impact of daily disease man-
agement of patients in non-research clinical settings.
Additionally, the observation period of the included
patients is limited to a maximum of 3 years (median fol-
low-up 2.2 years) of observation, thus limiting the ability
Screenshot from the OLAP-tool "Individual Risk Profile" displaying the demographics of the selected subgroup (blue)Figure 1
Screenshot from the OLAP-tool "Individual Risk Profile" displaying the demographics of the selected subgroup (blue). The 
green dot indicates the requested patient characteristics (RR disease course, baseline EDSS 2, age at onset 30 years, disease 
duration 36 months and 2 relapses in the last 12 months). In addition the distributions of all patients from the clinical trial data 
having the same course of the disease are displayed to give the user the impression on how representative the selected sub-
group for the selected course is (gray).Page 3 of 6
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with what is a life-long disease.
A comparison of the tool with population based preva-
lence cohorts [5-7] is the next step and this will test the
reliability of the tool. In the current version the individual
datasets consist of the standard variables (course, age at
onset, baseline EDSS, disease duration, and number of
relapses in the last 12 months). Although available, quan-
titative MRI variables were not included due to limitations
in availability in clinical practise and their relatively poor
additional predictive value for near-term clinical out-
comes compared to the other clinical variables [12].
Implementing more refined models especially for the
development of disease of progressive patients might
result in more valid course predictions. Including long-
term observational data from natural history studies that
cover 20–30 years would help to improve the core data
and likely the predictive ability [13,14] of the tool as well,
if potentially important predictors for the long-term dis-
ease evolution such as time to reach certain EDSS levels
(e.g. EDSS = 3, 4 and 6) and time-point of reaching the
secondary progressive phase of the disease will be
included.
In addition, the utility of the OLAP tool as a predictor of
disease course is limited by the patient characteristics in
the parent dataset. For instance, there are only a small
number of patients with a primary progressive course of
MS in the SLCMSR dataset, and this subtype cannot be
sufficiently analysed yet. The advantage of the OLAP tool
(compared with a purely model based prediction), how-
Screenshot from the OLAP-tool "Individual Risk Profile" displaying EDSS courses and regions of EDSS evolutionFigure 2
Screenshot from the OLAP-tool "Individual Risk Profile" displaying EDSS courses and regions of EDSS evolution. The interior 
band defines the middle 50% of EDSS courses. The other bands outline (from the inside to the outside) 75%, 90% and 95% of 
the individual disease courses. Additional information about the disease course is provided by the annual relapse rates. These 
are displayed as box plots and illustrate the disease activity.Page 4 of 6
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ure 1).
Conclusion
The "individual risk profile" project is based on a compre-
hensive database and the programming of an OLAP-tool.
Our initial intention is to pilot the use of the database
amongst neurologists and other researchers experienced
in MS with an interest in clinical trials. This phase should
provide informed feedback on the utility of the tool for
clinical or research use. Updated versions are planned
with expanded databases in particular inclusion of long-
term natural history data and a broader spectrum of pre-
dictors.
Most developmental steps of this project as well as princi-
ples of the creation of the underlying database are not dis-
ease-specific. It will be of interest to apply the methods
and software developed at the SLCMSR for studying MS to
other chronic diseases like heart failure, chronic obstruc-
tive pulmonary disease, or diabetes mellitus.
Availability and requirements
Project name: OLAP Individual Risk Profile
Project home page: https://www.slcmsr.net/public/
Operating systems: Web based application
Programming language: R, Java
Other requirements: CSS1/UTF-8 compliant browser is
required (e.g. Internet Explorer 5.5 or higher, Firefox 1.0
or higher)
License: Free, anyone may use the service for non-com-
mercial purposes.
Any restrictions to use by non-academics: No.
Competing interests
The author(s) declare that they have no competing inter-
est.
Screenshot from the OLAP-tool "Individual Risk Profile" displaying the Kaplan-Meier curves for the time to sustained progres-sion (6 m nths confirmation period) an  time to EDSS 6Figure 3
Screenshot from the OLAP-tool "Individual Risk Profile" displaying the Kaplan-Meier curves for the time to sustained progres-
sion (6 months confirmation period) and time to EDSS 6. For illustration purposes Kaplan-Meier curves are displayed for a 
SPMS population. In the background the curves for the population as defined in Figure 1 are displayed.Page 5 of 6
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Martin Daumer and Michael Scholz developed together
the idea, Michael Scholz implemented the first version of
the tool, and Christian Lederer planned and devised the
refined method. Christian Lederer and Anneke Neuhaus
programmed the current version of the OLAP-tool. Jerry
Wolinsky is chair of the SLC's scientific advisory commit-
tee and has tested and evaluated several versions of the
tool. All co-authors contributed in critically discussing the
overall concept, testing the tool in various stages of its
development in on site and during joint conference calls,
writing and critical reviewing the manuscript. All coau-
thors approved the final version of the manuscript.
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